<DOC>
	<DOCNO>NCT00187057</DOCNO>
	<brief_summary>This pilot/feasibility study design investigate feasibility treat child Ataxia-Telangiectasia ( A-T ) cancer regimens nearly intense non-A-T patient cancer would receive .</brief_summary>
	<brief_title>Study Treatment Cancer Children With Ataxia-telangiectasia</brief_title>
	<detailed_description>Approximately 10-30 % A-T patient develop malignancy lifetime . The vast majority cancer lymphoid origin . There consensus regard optimal strategy treat child A-T develop hematopoietic malignancy . Historically , many child treat therapy much less intensive conventional approach non-A-T patient similar malignancy correspond treatment era . Although less intensive approach may stem perception child would tolerate intensive therapy , fact data suggest child tolerate intensive therapy . However , clear child A-T require modification certain component intensive therapy . To provide child A-T either ALL malignant lymphoma best chance cure , propose use modern therapeutic strategy minimal modification address unique toxicity profile encounter treat child A-T . Secondary objective include : - To clinically biologically characterize malignancy occur child A-T ( usually malignant lymphoma ALL ) . This include vitro drug sensitivity screening . - To study chemotherapy-induced DNA damage child A-T . Detailed Description Treatment Plan : - Acute Lymphoblastic Leukemia ( ALL ) Low Risk : Induction : Prednisone 40 mg/m2/day PO day 1-28 Vinblastine 6 mg/m2/dose IV day 8 Vincristine 1.5 mg/m2/dose day 1 , 15 Daunomycin 20 mg/m2/week IV day 1,15 Asparaginase 10,000 U/m2/dose IM day 2 , 4 , 6 , 8 , 10 , 12 VP-16 225 mg/m2/dose Days 22 , 25 , 29 Ara-C 300 mg/m2/dose Days 22 , 25 , 29 All patient receive CNS therapy triple intrathecal therapy day 1 , 22 43 induction treatment , dose age adjust . Consolidation : Methotrexate 2 mg/m2 IV day 43 50 mercaptopurine 75 mg/m2 day 43-56 . Continuation therapy ( 120 week ) : Week : 1 . 6-MP + MTX 2 . 6-MP + MTX 3 . 6-MP + MTX 4 . Dex + VCR 5 . 6-MP + MTX 6 . 6-MP + MTX 7 . 6-MP + HDMTX 8 . Dex + VCR 9 . 6-MP + MTX 10 . 6-MP + MTX 11 . 6-MP + MTX 12 . Dex + VCR 13 . 6-MP + MTX 14 . 6-MP + MTX 15 . 6-MP + HDMTX This sequence repeat week 52 6-MP + MTX give weekly complete 120 week . IT MHA ( MTX , hydrocortisone , Ara-C ) week 1 , 2 , 7 , 15 every 4-8 week depend CNS status . Dosages , Schedules Routes : 6-MP 75 mg/m2 PO ; daily x 7 MTX 40 mg/m2 IM IV ; q ( every ) week ; Dex 6 mg/m2 PO ; 3 divide dos daily x 7 VCR 1.5 mg/m2 IV ( max . 2.0 mg ) HDMTX 2 g/m2 IV 2 hour , every 8 week Reinduction : Reinduction therapy ( week 16-21 ) . Reinduction therapy ( initial induction treatment minus dose 2 3 VP16 +ara-C minus day 22 intrathecal therapy ) give bone marrow examination week 15 confirms complete remission . - Acute Lymphoblastic Leukemia ( ALL ) - High Risk Induction : Prednisone 40 mg/m2/day PO ) divide 3 dos day 1-28 Vinblastine 6 mg/m2/dose IV day 8 Vincristine 1.5 mg/m2/dose day 1 , 15 Daunomycin 20 mg/m2/week IV day 1 , 15 Asparaginase 10,000 U/m2/dose IM day 2 , 4 , 6 , 8 , 10 , 12 , ( 15 , 17 , 19 ) VP16 225 mg/m2/dose day 22 , 25 , 29 Ara-C 300 mg/m2/dose day 22,25,29 All patient receive triple IT therapy day 1 , 22 43 induction additional IT therapy day 8 15 CNS leukemia ( CNS 2 CNS 3 ) present diagnosis . If require , patient CNS 2 3 diagnosis , IT therapy continue 2 consecutive CSF study normal ( i.e. , day 29 36 ) . Consolidation : HDMTX 2 mg/m2 IV day 43 50 6 MP 75 mg/m2 PO day 43-56 Continuation Therapy ( 120 week ) : Week : 1 . Dex + VCR 2 . VP-16 + CTX 3 . 6-MP + MTX 4 . MTX + Ara-C 5 . Dex + VCR 6 . VP-16 + CTX 7 . 6-MP + HDMTX 8 . 6-MP + MTX 9 . Dex + VCR 10 . VP-16 + CTX 11 . 6-MP + MTX 12 . MTX + Ara-C 13 . Dex + VCR 14 . VP-16 + CTX 15 . 6-MP + HDMTX These sequence repeat week 52 , 6MP/MTX give weekly complete 120 week . IT MHA ( MTX , hydrocortisone , Ara-C ) week 1 , 2 , 7 , 15 every 4-8 week depend CNS status risk status . Dosages , Schedules Routes : VP 16 225 mg/m2 IV week Cyclophosphamide 300 mg/m2 IV ( MESNA ) week addition 6 hour IV hydration 6-MP 75 mg/m2 PO ; daily x 7 MTX 40 mg/m2 IM IV week Ara-C 300 mg/m2 IV push ; week Dex 8 mg/m2/day PO ; 3 divide dos daily x 7 VCR 1.5 mg/m2 IV push ( max . 2.0 mg ) HDMTX 2 g/m2 IV 2 hour ; every 8 week x 7 - B-Cell Non-Hodgkins Lymphoma Overview - chemotherapy regimen use varies group base extent disease Group A Induction ( COPAD x 2 cycle ) : Cyclophosphamide 500 mg/m2/day ( divide every 12 hour ) IV ( MESNA ) Day 1 , 2 , 3 Vincristine 2.0 mg/m2 IV Day 1 Vinblastine 6 mg/m2 IV Day 6 Prednisone 60 mg/m2/day ( bid ) PO Day 1-5 Adriamycin 50 mg/m2 ( 6 hr ) IV Day 1 G-CSF 5 mcg/kg/day count recovery . Group B COP Induction : Cyclophosphamide 300 mg/m2 IV ( divide every 12 hour ) IV ( MESNA ) Day 1 Vincristine 1.0 mg/m2 IV Day 1 Prednisone 60 mg/m2/day ( divide bid ) PO day 1-7 CNS Therapy Intrathecal Day 1 - dose age adjust COPAD-M3 Induction x 2 cycle : Vinblastine 6 mg/m2 IV Day 1 HD MTX 3 mg/m2 IV 3 hour Day 1 leucovorin rescue CNS Therapy intrathecal age adjust Day 2 , 6 Cyclophosphamide 500 mg/m2/day ( second course 1 mg/m2/day ) IV ( MESNA ) Day 2 , 3 , 4 Adriamycin 50 mg/m2 IV Day 2 Prednisone 60 mg/m2 ( divide bid ) PO Day 1-5 G-CSF 5 mcg/kg/day count recovery CYM Consolidation x 2 cycle : HD MTX 3 mg/m2 IV 3 hour Day 1 leucovorin rescue Ara-C 100 mg/m2/day CI/IV ( x 5 day ) Day 2-6 CNS Therapy intrathecal age adjust Day 2 7 Maintenance : Prednisone 60 mg/m2/day ( divide bid ) PO Day 1-5 HDMTX 3 mg/m2 IV 3 hour Day 1 leucovorin rescue CNS Therapy intrathecal age adjust Day 2 Cyclophosphamide 500 mg/m2/day IV ( MESNA ) Day 2 , 3 Adriamycin 50 mg/m2 IV Day 3 Vincristine 2 mg/m2 IV Day 1 G-CSF 5 mcg/kg/day count recovery - Limited Stage Non-Hodgkins Lymphoma Induction : Vincristine 2 mg/m2 IV day 1 , 22 ( maximum dose 2 mg ) Vinblastine 6 mg/m2 IV , day 8 Prednisone 40 mg/m2/day 3 divided dos x 28 day Adriamycin 30 mg/m2/day IV one hour day 1 22 Cyclophosphamide 750 mg/m2/day IV day 1 22 Triple IT chemotherapy participant head neck primary tumor day 1 , 8 , 22 . Each dose age adjust . Consolidation - start day 43 : Adriamycin 30 mg/m2 IV Cyclophosphamide 750 mg/m2 Prednisone 40 mg/m2 3 divided dos x 5 day Vincristine 2.0 mg/m2 ( max . 2.0 mg ) IV Triple IT chemotherapy head neck primary day 43 64 . Maintenance : Maintenance chemotherapy administer patient lymphoblastic lymphoma consist 24 week chemotherapy oral daily 6-MP weekly oral methotrexate ( TIT every 6 week patient head neck primary ) induction/consolidation . - Hodgkins Disease Participants favorable disease receive VAMP chemotherapy : VAMP chemotherapy dose schedule : Vinblastine 6 mg/m2 , IV day 1 , 15 ( maximum dosage : 10 mg ) Adriamycin 25 mg/m2 , IV day 1 , 15 Methotrexate 20 mg/m2 , IV day 1 , 15 Prednisone 40 mg/m2 PO day 1-14 divide 3 daily dos Repeat cycle every 28 day , total number cycle = 6 ( NO RADIATION THERAPY ) Participants unfavorable disease receive VAMP COP : VAMP chemotherapy dos ( cycle 1 , 3 , 5 , 7 ) Vinblastine 6 mg/m2 IV day 1 , 15 Adriamycin 25 mg/m2 IV day 1,15 Methotrexate 20 mg/m2 IV day 1 , 15 Prednisone 40 mg/m2 ( divided 3 daily dos ) PO day 1-14 COP chemotherapy dos ( cycle 2 , 4 , 6 , 8 ) Cyclophosphamide 600 mg/m2 IV ( MESNA ) day 1 , 8 Vincristine 1.4 mg/m2 IV day 1,8 ( max dose 2 mg ) Procarbazine 100 mg/m2 PO day 1-14 ( NO RADIATION THERAPY )</detailed_description>
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Cerebellar Ataxia</mesh_term>
	<mesh_term>Telangiectasis</mesh_term>
	<mesh_term>Ataxia Telangiectasia</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Patient must diagnosis AtaxiaTelangiectasia ( AT ) . Patient must diagnosis either acute lymphoblastic leukemia ( ALL ) lymphoma ( nonHodgkin lymphoma Hodgkin 's disease ) . Patients malignancy ( solid tumor , rare malignancy , relapse hematopoietic malignancy ) eligible biologic study protocol ; receive best clinical management chemotherapy . Patients previously untreated . If prior chemotherapy already start ( induction ) , therapy continue accord protocol clinically appropriate time point . Patients diagnosis Ataxia Telangiectasia ( AT ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Ataxia</keyword>
	<keyword>alphafetoprotein</keyword>
</DOC>